Teresa I. Ng

Publications by Year

Research Areas

Hepatitis C virus research, HIV/AIDS drug development and treatment, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, Systemic Lupus Erythematosus Research

Most-Cited Works

• → Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection(2018)430 cited
• → Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis(2017)296 cited
• → Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis(2017)227 cited
• → Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment(2017)201 cited
• → Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study(2018)144 cited
• → Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure(2017)137 cited
• → In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir(2017)136 cited
• → Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology(2007)129 cited
• → Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro(2005)120 cited
• → In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450(2014)117 cited